Function, work productivity, and quality of life measures in a phase 3, randomized, placebo-controlled, double-blind, multicenter, 12-week study of the safety and efficacy of solriamfetol (JZP-110) for the treatment of excessive sleepiness in patients with obstructive sleep apnea

Introduction: Excessive sleepiness in patients with obstructive sleep apnea (OSA) is associated with reductions in health-related quality-of-life (HRQoL), impaired functioning at work, and negative impact on daily activities. The efficacy of solriamfetol (JZP-110), a selective dopamine norepinephrine reuptake inhibitor with wake-promoting effects, was evaluated in a phase 3 study in patients with excessive sleepiness due to OSA.
Source: Sleep Medicine - Category: Sleep Medicine Authors: Tags: Excessive Daytime Sleepiness (not Narcolepsy) Source Type: research